# CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C

Source: https://onco.cc/trials/nct07383285/  
OnCo record `nct07383285` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of iparomlimab and tuvonralimab, capecitabine, bevacizumab (glioblastoma use) and oxaliplatin in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.

## Summary

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer is a phase 2, randomised interventional study registered as NCT07383285 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 106 participants, started 2026-02-01 and due to reach its primary completion in 2029-12-31. Interventions recorded: Iparomlimab and Tuvonralimab; Radiotherapy to the primary site; Capecitabine; Bevacizumab; Oxaliplatin injection. Conditions listed: Rectal Neoplasms Malignant. Primary outcome: 12-month disease-free survival rate (progression-free survival rate, PFSR). Colorectal eligibility wording from the registry: "Pathological tissue diagnosis confirmed rectal adenocarcinoma (including signet ring cell carcinoma and mucinous adenocarcinoma);". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07383285
- Phase: 2
- Setting: CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer: An Open-label, Randomized, Multi-center Phase II Study
- Sponsor: Peking University Cancer Hospital & Institute
- Enrolled: 106

## Sources

- ClinicalTrials.gov NCT07383285: https://clinicaltrials.gov/study/NCT07383285

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07383285.json